SecBot SecBot
144 ·Filed Jun 15, 2026

ARDX

ARDELYX, INC.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001950047-26-006116
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The sale is routine and pre-planned under a 10b5-1 program, with consistent monthly sales observed. No material negative signal — monitor for any acceleration in insider selling or changes to the 10b5-1 plan.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ARDX ▼ -36.16% at T+60d
NEUTRAL call -36.16% · α vs SPY -37.15% · entry $5.67 → $3.62
Entry = T+0 close
Jun 15, 2026
via day close
T+1d
+3.00%
call +3.00% · α +4.25%
$5.84
settled 4mo ago
T+5d
+8.99%
call +8.99% · α +11.23%
$6.18
settled 4mo ago
T+20d
-8.99%
call -8.99% · α -9.19%
$5.16
settled 3mo ago
T+60d
-36.16%
call -36.16% · α -37.15%
$3.62
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Director Michael Raab filed a Form 144 notice of intent to sell 125,000 shares of Ardelyx common stock, with an approximate market value of $711,250 as of the filing date. The shares are to be sold through Morgan Stanley and include shares acquired from stock option exercises, restricted stock unit vesting, and employee stock purchase plan purchases. The filing indicates a pre-arranged 10b5-1 trading plan, with prior sales under the plan in March, April, and May 2026.

Key Facts

  • Director Michael Raab filed Form 144 to sell 125,000 shares of ARDX common stock.
  • Estimated sale value: $711,250 based on filing date.
  • Sale is part of a pre-arranged 10b5-1 trading plan with prior sales in March, April, and May 2026.
  • Shares to be sold include those from stock option exercises, RSU vesting, and ESPP purchases.
  • Raab is both a director and officer of Ardelyx.

Financial Impact

Proposed sale of 125,000 shares valued at approximately $711,250, representing roughly 0.05% of Ardelyx's $1.4B market cap.

dilution

Risk Factors

  • Insider selling could increase if the 10b5-1 plan is expanded or if other insiders follow suit.
  • No direct operational risk from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006116
Document: 0001950047-26-006116-index.html0001950047-26-006116
Document: 0001950047-26-006116.txt0001950047-26-006116
16 reports for ARDX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ARDX — sortable, filterable
TypeNow
Oct 5, 2026
22d ago
Press Release
NEUTRAL ★ 2/10
$3.39awaiting T+20—$2.99 (−11.73%)
Aug 25, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.83 $3.45▼ −9.92%▼ −10.15%$2.99 (−21.87%)
Aug 25, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$3.83 $3.45▼ −9.92%▼ −10.15%$2.99 (−21.87%)
Aug 21, 2026
9w ago
144
NEUTRAL ★ 2/10
$3.74 $3.62▼ −3.21%▼ −4.52%$2.99 (−19.99%)
Aug 21, 2026
9w ago
144
NEUTRAL ★ 2/10
$3.74 $3.62▼ −3.21%▼ −4.52%$2.99 (−19.99%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$3.92 $3.40▼ −13.27%▼ −12.28%$2.99 (−23.66%)
Aug 15, 2026
10w ago
Institutional Cluster
BULLISH ★ 4/10
$4.06 $3.52▼ −13.30%▼ −11.77%$2.99 (−26.30%)
Jul 2, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$5.27 $5.04▼ −4.36%▼ −3.95%$2.99 (−43.22%)
Jun 17, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$6.05 $5.13▼ −15.29%▼ −15.82%$2.99 (−50.54%)
Jun 15, 2026
19w ago
144
NEUTRAL ★ 3/10
$5.67 $5.16▼ −8.99%▼ −9.19%$2.99 (−47.22%)
Showing 10 of 16

US Market Status

Market Open — Closes in 3h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026